Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oremepermin alfa - Kringle Pharma

Drug Profile

Oremepermin alfa - Kringle Pharma

Alternative Names: Hepatocyte growth factor - Kringle Pharma; KP-100 - Kringle Pharma; KP-100IT; KP-100LI

Latest Information Update: 13 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kringle Pharma
  • Class Antifibrotics; Growth factors; Neuropsychotherapeutics
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Cell death inhibitors; Proto-oncogene protein c-met modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Scars; Spinal cord injuries
  • Phase II Amyotrophic lateral sclerosis
  • No development reported Acute kidney injury

Most Recent Events

  • 24 Nov 2022 Phase-III clinical trials in Scars in Japan (Submucosal)
  • 18 Nov 2022 Kringle Pharma plans a phase III trial for Scar in Japan (Injection) (NCT05627648)
  • 07 Sep 2022 Phase III development in Spinal cord injuries (In adults, In the elderly) is ongoing in Japan (Intrathecal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top